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Background: Cross-sectional studies have suggested that serum omega-3 (n-3) and omega-6 (n-6) polyunsaturated
fatty acids (PUFAs) are related to favorable lipoprotein particle concentrations. We explored the associations of
serum n-3 and n-6 PUFAs with lipoprotein particle concentrations and sizes in a general population cohort at
baseline and after 6 years.
Findings: The cohort included 665 adults (274 men) with a 6-year follow-up. Nutritional counseling was given at
baseline. Serum n-3 and n-6 PUFAs and lipoprotein particle concentrations and the mean particle sizes of VLDL,
LDL, and HDL were quantified by nuclear magnetic resonance (NMR) spectroscopy for all baseline and follow-up
samples at the same time. Concentrations of n-3 and n-6 PUFAs were expressed relative to total fatty acids. At
baseline, n-3 PUFAs were not associated with lipoprotein particle concentrations. A weak negative association was
observed for VLDL (P = 0.021) and positive for HDL (P = 0.011) particle size. n-6 PUFA was negatively associated with
VLDL particle concentration and positively with LDL (P < 0.001) and HDL particle size (P < 0.001). The 6-year change
in n-3 PUFA correlated positively with the change in particle size for HDL and LDL lipoproteins but negatively with
VLDL particle size. An increase in 6-year levels of n-6 PUFAs was negatively correlated with the change in VLDL
particle concentration and size, and positively with LDL particle size.
Conclusion: Change in circulating levels of both n-3 and n-6 PUFAs, relative to total fatty acids, during 6 years of
follow-up are associated with changes in lipoprotein particle size and concentrations at the population level.
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Circulating polyunsaturated fatty acids (PUFAs) may re-
flect dietary PUFAs although they may also be influenced
by other factors such as obesity and insulin resistance.
There is observational evidence that dietary intake
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article, unless otherwise stated.lipoprotein profile especially with higher concentrations of
HDL-particles and larger HDL particle size but also with
lower concentrations of LDL particles and larger LDL par-
ticle size and decreasing concentration of VLDL particles
and smaller VLDL particles [1,2]. However, daily treatment
with n-3 fatty acids has not convincingly been associated
with reduced cardiovascular morbidity and mortality [3,4].
It has been suggested that blood level of n-3 PUFAs
may be a better indicator of cardiovascular risk than n-3
supplementation [5]. Omega-6 (n-6) PUFAs may reduce in-
flammation, insulin resistance and decreases the risk oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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of n-6 PUFAs related to decreasing cardiovascular diseases
and mortality remains to established [7].
Motoyama et al. have shown that circulating serum n-
6 and n-3 PUFAs are inversely related to triglycerides in
middle aged men in several cross-sectional studies [8].
Higher serum concentrations of n-6 PUFAs are further
associated with lower concentrations of LDL particles
and large VLDL particles and a higher concentration of
large HDL particles [9]. However, no study has assessed
the longitudinal changes of serum n-3 and n-6 PUFAs
and their associations with changes in lipoprotein par-
ticle concentrations and sizes at the population level.
We therefore analyzed the longitudinal associations be-
tween changes in serum n-3 and n-6 PUFA concentra-
tions with corresponding changes of lipoprotein particle
concentrations and sizes in a population-based setting
during 6-year follow-up.
Methods
Study population
All of the inhabitants in the town of Pieksämäki,
Finland, who were born in 1942, 1947, 1952, 1957, and
1962 (n = 1,294) were invited for a health check-up in
1997-1998 (baseline visit) and again in 2003-2004 At the
Primary Health Care Unit in Pieksämäki, Finland. Of
those invited, 923 (71%) participated in the first check-
up [10]. Of these, 688 subjects (74.5%) attended the sec-
ond health check-up six years (mean follow-up period)
later. All variables analysed in the present study were
available from 665 subjects (274 men and 391 women).
During the first health examination, the nurses were
instructed to counsel all the participants to embrace
more healthy lifestyles, including advising them to re-
place hard fats (e.g. butter, greasy milk, greasy red meat)
with smooth fats (e.g. vegetable oil, chicken, fish) and
liquid margarines, use olive oil or rapeseed oil in prepar-
ing food, and increase the consumption of fish. The
protocol was approved by the Ethics Committee of Kuo-
pio University Hospital. All of the participants gave their
informed written consent.
Clinical and laboratory procedures
Both health check-ups were performed by the same two
nurses. Waist circumference was measured and body mass
index (BMI) was calculated. Blood samples were taken after
an overnight fast. Glucose and serum lipids were measured
by standard enzymatic methods [10] from fresh serum sam-
ples and analyzed in the laboratory of the Kuopio Univer-
sity Hospital. Insulin was determined by Phadeseph Insulin
Radio Immunoassay (RIA) 100 method (Pharmacia Diag-
nostics AB, Uppsala, Sweden). Concentrations of lipopro-
tein subclass particles were analysed by high-throughput
nuclear magnetic resonance (NMR) spectroscopy of nativeserum samples as described previously [11-14]. The mean
size of the VLDL, LDL, and HDL particles was calculated
by weighting the corresponding subclass diameters with
their particle concentrations. The diversity of fatty acid sat-
uration was quantified from serum extract samples [13].
NMR spectroscopy was used conducted for all baseline and
follow-up samples at the same time in 2009. For statistical
analysis, the ratios of PUFA concentrations (mmol/L) to
total fatty acid concentration (mmol/L) were examined.
Statistical methods
The data are presented as means with standard deviations.
The 95% confidence intervals for the lipoprotein particle
concentrations and sizes were obtained by bias-corrected,
accelerated bootstrapping (5000 replications). Statistical sig-
nificance for hypotheses of linearity was evaluated by ana-
lysis of variance (ANOVA), Jonckheere-Terpstra test, or
Cochran-Armitage test. Linearity across the particle con-
centrations of tertiles of n-3 and n-6 PUFAs was tested by
using bootstrap-type general linear models with an appro-
priate contrast adjusted for age, sex, smoking and BMI,
antihyperglycemic medication and lipid-lowering medica-
tion at baseline. Respectively, associations between the
change in n-3 and n-6 PUFAs% with changes in total
VLDL, LDL, and HDL particle concentrations and mean
particle sizes during follow-up were estimated with regres-
sion analysis using Sidak-adjusted probabilities. These lon-
gitudinal changes were adjusted for age, sex, smoking and
BMI, antihyperglycemic medication and lipid-lowering
medication at baseline. Repeated data (relative change over
time) were analysed using generalising estimating equations
(GEE) models with the unstructured correlation structure.
Generalized estimating equations were developed as an ex-
tension of the general linear model (eg, OLS regression
analysis) to analyze longitudinal and other correlated data.
Results
Table 1 shows the baseline characteristics of the study
population by gender. The mean age was 46 years and
BMI 26.5 kg/m2. The use of lipid lowering, antihyperten-
sive and glucose lowering agents was not frequent in the
study population at baseline.
Table 2 shows the mean particle concentrations and the
particle sizes of VLDL, LDL, and HDL across tertiles of n-
3 and n-6 PUFA concentrations, relative to total fatty acids.
No significant associations were observed between n-3
PUFAs and concentrations of lipoprotein particles. How-
ever, serum n-3 PUFAs was negatively associated with
VLDL particle size (P = 0.021) and positively with HDL
particle size (P = 0.011). There was a strong negative rela-
tionship between n-6 PUFAs and VLDL particle concen-
tration whereas n-6 PUFAs did not associate with LDL and
HDL particle concentrations. There was a negative linear
trend for VLDL particle size and positive linear trend for
Table 1 Baseline characteristics of the study population
Women Men P-value
N = 391 N = 274
Age, years, mean (SD) 46 (6) 46 (6) 0.52
Body mass index, kg/m2, mean (SD) 26.3 (5.2) 26.8 (3.6) 0.21
Waist, cm, mean (SD) 83 (23) 94 (10) <0.001
Lipid lowering medication, n (%) 5 (1) 11 (4) 0.023
Antihypertensive medication, n (%) 36 (9) 33 (12) 0.24
Antihyperglycemic medication, n (%) 1 (0) 6 (2) 0.022
Total cholesterol, mmol/L, mean (SD) 5.6 (0.97) 5.7 (0.98) 0.047
HDL cholesterol, mmol/L, mean (SD) 1.5 (0.33) 1.3 (0.30) <0.001
Triglycerides, mmol/L, mean (SD) 1.2 (0.63) 1.6 (0.92) <0.001
Glucose, mmol/L, mean (SD) 5.6 (0.59) 5.9 (0.96) <0.001
Insulin, mU/L, mean (SD) 9.9 (7.3) 10.3 (5.2) 0.38
Current smoking, n (%) 80 (21) 77 (27) 0.024
Reported use of alcohol, n (%) 309 (79) 239 (88) 0.004
Table 2 Baseline VLDL, LDL and HDL particle concentrations
Tertiles o
(Percentage of total f
I
<3.16% 3.16%
VLDL, mean (SD)
Concentration, nmol/L 84.8 (26.7) 93.0
Mean size, nm 36.4 (1.31) 36.5
LDL, mean (SD)
Concentration, nmol/L 543 (119) 563
Mean size, nm 23.5 (0.17) 23.5
HDL, mean (SD)
Concentration, μmol/L 7.25 (0.79) 7.36
Mean size, nm 9.92 (0.23) 9.93
Tertiles o
I
<32.7% 32.7%
VLDL, mean (SD)
Concentration, nmol/L 110 (29.3) 82.5
Mean size, nm 37.4 (1.32) 36.1
LDL, mean (SD)
Concentration, nmol/L 589 (122) 537
Mean size, nm 23.5 (0.19) 23.6
HDL, mean (SD)
Concentration, μmol/L 7.28 (0.84) 7.35
Mean size, nm 9.85 (0.20) 9.97
*adjusted for age, sex, smoking, BMI and antihyperglycemic medication and lipid-lo
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centrations. Compared to n-3 PUFAs, the relationships
between n-6 PUFAs and lipoprotein particle sizes were
stronger (all P < 0.001).
In general, VLDL particle concentration and size
increased (P < 0.001) and HDL particle concentration
decreased (P < 0.001) whereas no significant changes
were found for LDL particle concentrations and for
LDL and HDL particle sizes (Additional file 1: Figure
S1). Mean change of triglycerides (men and women
together) was -0.05 mmol/L (95% CI: -0.11 to 0.01 mmol/L).
Table 3 shows the partial correlations of 6-year changes in
serum n-3 and n-6 (in% of total fatty acids) with changes in
VLDL, LDL, and HDL lipoprotein particle concentrations
and mean particle sizes. The change in serum n-3 PUFAs
during follow-up correlated positively with the change in
LDL particle size (r = 0.13) and HDL particle size (r = 0.12)
although the correlations were weak. Modest inverse correl-
ation (r = -0.20) was found between the changes of n-3
PUFAs and VLDL particle size. The change of n-3 PUFAs
was not associated with changes in VLDL, LDL and HDL
particle concentrations during follow-up (P > 0.05 for all).and sizes according to n-3 PUFA and n-6 PUFA tertiles
f N-3 PUFAs
atty acid concentration)
II III
to 3.87% >3.87% P for linearity*
(30.4) 87.1 (30.4) 0.81
(1.39) 36.1 (1.21) 0.021
(122) 557 (121) 0.91
(0.18) 23.5 (0.15) 0.084
(0.82) 7.46 (0.79) 0.086
(0.24) 9.98 (0.24) 0.011
f N-6 PUFAs
II III
to 36.1% >36.1% P for linearity*
(22.6) 72.3 (20.7) <0.001
(0.99) 35.6 (0.81) <0.001
(117) 537 (116) 0.15
(0.14) 23.6 (0.13) <0.001
(0.82) 7.44 (0.75) 0.28
(0.23) 10.0 (0.25) <0.001
wering medication at baseline.
Table 3 Partial correlations between changes in n-3 and n-6 PUFAs (in % of total fatty acids) and changes in
lipoprotein particle concentrations and mean sizes
Change of
n-3 PUFAs n-6 PUFAs
r (95% CI)# r (95% CI)#
Change of
VLDL particle concentration −0.05 (-0.12 to 0.02) −0.37 (-0.44 to -0.30)***
VLDL particle mean size −0.20 (-0.28 to -0.12)*** −0.55 (-0.61 to -0.48)***
LDL particle concentration −0.02 (-0.07 to 0.05) 0.00 (-0.06 to 0.06)
LDL particle mean size 0.13 (0.06 to 0.20)** 0.34 (0.26 to 0.42)***
HDL particle concentration 0.09 (0.00 to 0.18) −0.08 (-0.16 to 0.02)
HDL particle mean size 0.12 (0.04 to 0.20)* 0.05 (-0.03 to 0.14)
#The 95% confidence intervals were obtained by bias-corrected bootstrapping (5,000 replications).
Sidak-adjusted probabilities. Adjusted for age, sex, smoking, BMI and antihyperglycemic medication and lipid-lowering medication at baseline.
*<0.05 **<0.01 ***<0.001.
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the change in VLDL particle concentration (r = -0.37)
and VLDL particle size (r = -0.55); the correlation with
change in LDL particle size was positive (r = 0.34). The
change in n-6 PUFAs was not significantly correlated
with the change in HDL particle concentration and size
or with change in LDL particle concentration.
Discussion
The present population-based study comprising 665
middle-aged subjects showed that serum levels of both n-
3 and n-6 PUFA, relative to total fatty acids, were associ-
ated with lipoprotein particle concentrations and sizes.
Longitudinal changes in these fatty acid proportions paral-
leled various changes in lipoprotein particle numbers and
sizes. This appears to be the first study showing longitu-
dinal association between changes in serum PUFA levels
and lipoprotein particle concentrations in a population
consuming their habitual diet. The baseline results of the
present study are in line with the previous cross-sectional
study of 1098 men conducted by Choo et al. [9].
Previously, Motoyama et al. found in the population-
based large study that n-6 and n-3 PUFAs were inversely
related to serum triglycerides which are carried by VLDL
[8]. VLDL lipoprotein has been found to associate with in-
creased cardiovascular risk [15]. In line with the previous
study by Choo et al. [9] higher n-6 PUFA concentration at
baseline associated with smaller VLDL particle size and
concentration in the present study. However there was not
a clear association between n-3 PUFAs and VLDL particles
at baseline. In addition, the strongest longitudinal correla-
tions were found for the negative associations between n-6
PUFAs and VLDL particle concentration and size. Small
low-density lipoprotein particles have been shown to be a
cardiovascular risk factor predicting coronary artery disease
and events [16-18]. In the present study, there was not
a difference in LDL particle sizes between n-3 tertiles atbaseline and the difference between n-6 PUFA tertiles was
only modest. However, the present findings suggest that the
change of PUFA levels, especially n-6 PUFAs, associate
positively with the change of LDL particle size. Increased
circulating levels of n-3 and n-6 PUFAs may contribute to
favorable non-HDL (LDL and VLDL) particle changes.
Serum PUFA concentrations showed an association with
mean HDL particle size at baseline. In addition, the
change of n-3 PUFAs correlated with the change in HDL
particle size. The FinnTwin-study suggested that a higher
consumption of n-3 PUFA was related to changes in HDL
subspecies toward a larger mean particle size in men [1].
That association remained significant in analyses control-
ling for genetic and environmental influences and for con-
founding factors like BMI, smoking and physical activity.
Here we were able to control for additional potential con-
founding factors which yielded consistent findings with
the FinnTwin-study.
The serum concentrations of fatty acids are generally
regarded as markers of dietary intake although adiposity
and genetics may contribute [19]. We did not assess the
macronutrient dietary intake from this population. In the
population-based Kuopio Ischemic Heart Disease (KIHD)
study dietary intake of PUFAs correlated with serum
PUFAs (r = 0.50) [20]. The KIHD study was performed in
an area in close proximity of this study area and subjects
in both KIHD and in this study share similar socio-
demographic characteristics. The Cardiovascular Risk in
Young Finns Study provided consistent findings about the
relationship between dietary intake and serum levels of
PUFAs as quantified by NMR spectroscopy [21]. We as-
sume that serum PUFA levels in the present study primar-
ily reflect dietary intake of PUFAs. It is possible that most
pronounced change in the dietary habits was the change
in fat quality. In the lake area of this study population, the
potential increased intake of n-3 PUFAs was most likely
from the lean white fish [22]. However, these assumptions
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not have the measurement of diet.
The observational nature of this study, with only two
health checkups and missing dietary intake information
may be taken as a limitation. However, the present study
represents a general population with several years of
follow-up and with measurements of the circulating lipo-
protein particle profile as well as PUFAs conducted for all
baseline and follow-up samples at the same time.
In conclusion, at the population level, the 6-year rela-
tive increases in serum levels of both n-3 and n-6 PUFAs
are associated with concurrent favorable changes in the
lipoprotein particle profile among men and women with
a mean age of 46 years.Additional file
Additional file 1: Figure S1. Relative change over time of 6 years (from
baseline to follow-up) of VLDL, LDL and HDL lipoprotein concentrations
and sizes adjusted for age, sex, smoking, BMI and antihyperglycemic
medication and lipid-lowering medication at baseline. Figure
representing total changes of main outcome measures.
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